A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

This study is testing a combination of evofosfamide (a drug that activates inside low-oxygen tumor areas) with two immunotherapy drugs (zalifrelimab and balstilimab) in people with advanced castration-resistant prostate cancer, pancreatic cancer, or HPV-negative head and neck cancer. The combination aims to attack tumors that have been resistant to standard treatments. **You may be eligible if...** - You have advanced prostate, pancreatic, or head-and-neck cancer with no remaining standard treatment options - Your general health is fair to good (ECOG 0–2) - You have measurable or evaluable disease on imaging - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have uncontrolled serious infections or autoimmune conditions requiring systemic treatment - You have significant heart problems or clotting disorders - You have received prior immunotherapy for this cancer Talk to your doctor to see if this trial is right for you.